TITLE

DEXTROTHYROXINE FOR LOWERING SERUM CHOLESTEROL

AUTHOR(S)
Bechtol, L.D.; Warner, W.L.
PUB. DATE
November 1969
SOURCE
Angiology;Nov1969, Vol. 20 Issue 10, p565
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Sodium dextrothyroxine, in daily doses of 2 to 8 mg, is effective in lowering elevated serum cholesterol in both hypothyroid and euthyroid patients. This effect is somewhat greater in hypothyroid than in euthyroid patients, and is sustained for at least three years of therapy and beyond. The drug, when administered in a proper dosage schedule, is useful for the treatment of hypothyroidism is cardiac patients who cannot tolerate other types of thyroid medication. The side effects attributable to the drug are, for the most part, caused by increased metabolism. Adverse effects are more commonly seen in patients with hypothyroidism and/or coronary artery disease than in euthyroid patients without cardiac disease. Adverse change in cardiac status is not a significant problem in noncardiac patients, whether euthyroid or hypothyroid. In cardiac patients, such changes can be minimized by proper patient selection and attention to dosage schedules. Although not observed in very elderly patients, the mortality rate of D-thyroxine-treated patients is no higher than anticipated, especially in the noncardiac group, and may be lower than expected. Since the significant side effects are largely metabolic and appear to be dose related, it seems advisable to initiate therapy at low dosage levels (1 or 2 mg daily) and to increase the dose gradually until the desirable therapeutic range is reached. The maximum dose is dependent on individual patient tolerance, which may vary with thyroid and cardiac status and probably should be limited to 8 mg daily.
ACCESSION #
16394687

 

Related Articles

  • Comparing Tolerability of Olanzapine in Schizophrenia and Affective Disorders. Moteshafi, Hoda; Zhornitsky, Simon; Brunelle, Sarah; Stip, Emmanuel // Drug Safety;2012, Vol. 35 Issue 10, p819 

    Background: Olanzapine is prescribed for a number of psychiatric disorders, including schizophrenia, bipolar mania, and unipolar and bipolar depression. Olanzapine treatment is associated with tolerability issues such as metabolic adverse effects (e.g. weight gain, increase in blood glucose,...

  • Simvastatin Inhibits Glucose Metabolism and Legumain Activity in Human Myotubes. Smith, Robert; Solberg, Rigmor; Jacobsen, Linn L√łkken; Voreland, Anette Larsen; Rustan, Arild Christian; Thoresen, G. Hege; Johansen, Harald Thidemann // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Simvastatin, a HMG-CoA reductase inhibitor, is prescribed worldwide to patients with hypercholesterolemia. Although simvastatin is well tolerated, side effects like myotoxicity are reported. The mechanism for statin-induced myotoxicity is still poorly understood. Reports have suggested impaired...

  • Enoxaparin sodium.  // Reactions Weekly;4/7/2007, Issue 1146/1147, p16 

    The article presents the case of a 69-year-old man who developed intramuscular haematoma during enoxaparin sodium treatment for acute coronary syndrome. Given SC periumbilical enoxaparin sodium 60 milligrams twice daily, aspirin, perindopril and isosorbide mononitrate, he exhibited severe left...

  • Captopril: five years on. Hodsman, G.P.; Robertson, J.I.S. // British Medical Journal (Clinical Research Edition);9/24/1983, Vol. 287 Issue 6396, p851 

    Focuses on the efficacy of captopril since its introduction. Evidence of good patient tolerance to the drug; Adverse effects of captopril; Components of the drug's antihypertensive action.

  • Multiple drug intolerance syndrome: risk factors examined.  // Reactions Weekly;Dec2014, Vol. 1530 Issue 1, p9 

    An abstract of the article "Multiple Drug Intolerance Syndrome: A Large-Scale Retrospective Study," by H. M. Omer and colleagues is presented.

  • "Well tolerated" is intolerable. Aronson, Jeffrey K. // BMJ: British Medical Journal;2/20/2016, Vol. 352 Issue 8045, p281 

    The article discusses the incorrect use of the term well tolerated in referring to drugs and suggests that the concept of drug tolerability is poorly defined.

  • Phytosterols for dyslipidemia. Malinowski, Jennifer M.; Gehret, Monica M. // American Journal of Health-System Pharmacy;7/15/2010, Vol. 67 Issue 14, p1165 

    Purpose. The efficacy and safety of phytosterols for the management of dyslipidemia are reviewed. Summary. Phytosterols have been evaluated in over 40 clinical trials. The incorporation of 2 g of phytosterols daily into margarine, mayonnaise, orange juice, olive oil, low-fat milk, yogurt, and...

  • Thyroxine: anatomy of a health scare. Faasse, Kate; Cundy, Tim; Petrie, Keith // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/2/2010, Vol. 340 Issue 7736, p20 

    The article discusses the adverse reaction reports relating to the new formulation of thyroxine replacement therapy Eltroxin introduced by GlaxoSmithKline in New Zealand. According to some reports, the new formulation of the Eltroxin brand resulted in a change in the tablets' inert ingredients...

  • Patient-reported ADRs with T4 therapy sparks DHMA guidance.  // Reactions Weekly;Dec2014, Vol. 1532 Issue 1, p6 

    The article presents the guidance message issued to doctors by the Health and Medicines Authority (DHMA) in Denmark to clarify enquiries and adverse drug reaction (ADR) reports about Eltroxin and Euthyrox for treatment of hypothyroidism.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics